EC
VOR icon

EntryPoint Capital’s Vor Biopharma VOR Stock Holding History

EntryPoint Capital’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Buy
+10,785
New +$163K 0.05% 698

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

EntryPoint Capital's VOR Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Vor Biopharma (VOR) in Q2 2026: 10,785 shares worth $199K. The stake represents 0.05% of the portfolio and ranks #698 among its holdings.

102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • EntryPoint Capital held 10,785 shares of Vor Biopharma worth $199K as of Q2 2026.
  • Vor Biopharma was a new EntryPoint Capital position in Q2 2026.
  • Vor Biopharma made up 0.05% of EntryPoint Capital's portfolio in Q2 2026, its #698 holding.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.